Free press releases distribution network?

Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Thomas Platts-Mills, to Present at GTC’s Allergy Drug Discovery Conference in San Diego, California - Thomas Platts-Mills, to Present ‘The Significance of IgE Antibodies to Galactose-alpha -1, 3-Galactose (alpha-gal)’ at GTC’s Allergy Drug Discovery Conf., San Diego, January 31-February 1
Thomas Platts-Mills, to Present at GTC’s Allergy Drug Discovery Conference in San Diego, California

 

PRZOOM - /newswire/ - Monrovia, CA, United States, 2012/11/14 - Thomas Platts-Mills, to Present ‘The Significance of IgE Antibodies to Galactose-alpha -1, 3-Galactose (alpha-gal)’ at GTC’s Allergy Drug Discovery Conf., San Diego, January 31-February 1.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Thomas Platts-Mills, Division Head of Allergy, Asthma & Immunology at the University of Virginia, will be giving a presentation entitled,“The Significance of IgE Antibodies to Galactose-alpha -1, 3-Galactose (alpha-gal)” at GTC’s 2nd Allergy & Respiratory Drug Discovery Conference taking place in San Diego, CA on January 31st – February 1st, 2013.

In 2008, Dr. Platts-Mills’ lab reported that the monoclonal antibody cetuximab (erbitux) was causing anaphylaxis on first infusion because of pre-existing IgE specific for the glycosylation (Chung et al NEJ Med 2008). In addition, they established that the IgE were specific for alpha-gal, which was produced by the mouse cell line. In 2009, they identified a novel form of anaphylaxis to red meat which was also related to IgE specific for alpha-gal (Commins et al JACI 2009). The distribution of IgE specific for alpha-gal in the USA is primarily in the South East, and an important if not the only cause of these antibodies is bites from the lone star tick Amblyommaamericanum (Commins et al JACI 2011). His lab has identified an ecto-parasite induced IgEab response that can create a risk with the use of recombinant molecules made in mammalian cell lines. Alpha-gal on cetuximab is on the FAB portion of the heavy chain, by contrast in some other monoclonals this oligosaccharide is present on the Fc glycosylation site. Together with Dr. Parren, Dr. Platts-Mills has recently reported that this Fc site is not exposed in an intact IgG and is not capable of causing reactions (Nature Biotech, 2011). The specific problem is unlikely to occur again because i) most new MAb don’t have a glycosylation site on the FAB portion and ii) glycosylation on the Fc portion does not create a risk. However, the experience with cetuximab proves a clear warning that post-translational changes in a recombinant molecule can create a target for pre-existing IgE antibodies.

Thomas A. E. Platts-Mills, Ph.D., is the Oscar Swineford Jr. Professor of Medicine and head of the Asthma and Allergic Disease Center at the University of Virginia. Dr. Platts-Mills has carried out research in many different aspects of the role of indoor allergens in asthma.

Dr. Platts-Mills is the former president of the American Academy of Allergy Asthma and Immunology (AAAAI) and has been active in educational efforts nationally for twenty years. He has published over 300 papers and has been a member of the Editorial Board of more than 10 journals. In addition, he was a member of the Immunological Sciences Study Section for the NIH and in 2003, was chairman of the special interest study section on Asthma and Allergic disease for NIAID.

Dr. Platts-Mills has also served on the NAEPP for NHLBI. He has trained more than twenty specialists in Allergic Disease and has supervised eight PhD’s. He received his degree in Animal Physiology from Oxford University (1963) and his MD from St Thomas Hospital. In 1981 he was made a member of the Royal College of Physicians in London and became a fellow in 1982. He did his training in Allergy and Immunology with Dr. Ishizaka and Dr. Lictenstein at John Hopkins (1971-1974) and in 1983 received a PhD in Immunology from London University. He became a member of the Royal Society in 2010.

This conference is also part of the 2nd Novel Immunotherapeutics Summit, which consists of this track and three other tracks:
11th Cytokines & Inflammation
5th Immunotherapeutic & Immunomonitoring
Immunogenicity & Immunotoxicity

Over 200 leading industrial and academic experts will present at this two-day summit. The Novel Immunotherapeutics Summit will offer an in-depth examination of the challenges involved in the dynamic and ever-changing field of drug discovery and development.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Thomas Platts-Mills, to Present at GTC’s Allergy Drug Discovery Conference in San Diego, California

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  RightITnow Ltd

Visit  JobsWare.com

Visit  BizJobs.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today